Elotuzumab for Smoldering Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Smoldering Multiple Myeloma+7 More
Elotuzumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers understand how well a combination of elotuzumab, lenalidomide, and dexamethasone works in treating people with smoldering multiple myeloma.

Eligible Conditions
  • Smoldering Multiple Myeloma
  • Smoldering myeloma
  • Smoldering Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Smoldering Multiple Myeloma

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 4 years

2 Years
Overall survival
Proportion of patients who are progression free at 2 years
Response rate
4 years
Safety of the combination therapy
Time to progression

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Smoldering Multiple Myeloma

Trial Design

2 Treatment Groups

Elo / Len / Dex
1 of 2
Elo / Len
1 of 2
Experimental Treatment

51 Total Participants · 2 Treatment Groups

Primary Treatment: Elotuzumab · No Placebo Group · Phase 2

Elo / Len / DexExperimental Group · 3 Interventions: Lenalidomide, Elotuzumab, Dexamethasone · Intervention Types: Drug, Drug, Drug
Elo / LenExperimental Group · 2 Interventions: Lenalidomide, Elotuzumab · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenalidomide
FDA approved
Elotuzumab
FDA approved
Dexamethasone
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years

Who is running the clinical trial?

Blood Cancer Research PartnershipOTHER
4 Previous Clinical Trials
213 Total Patients Enrolled
2 Trials studying Smoldering Multiple Myeloma
83 Patients Enrolled for Smoldering Multiple Myeloma
Dana-Farber Cancer InstituteLead Sponsor
1,012 Previous Clinical Trials
393,308 Total Patients Enrolled
7 Trials studying Smoldering Multiple Myeloma
1,967 Patients Enrolled for Smoldering Multiple Myeloma
Bristol-Myers SquibbIndustry Sponsor
2,481 Previous Clinical Trials
3,919,545 Total Patients Enrolled
3 Trials studying Smoldering Multiple Myeloma
150 Patients Enrolled for Smoldering Multiple Myeloma
Multiple Myeloma Research ConsortiumNETWORK
18 Previous Clinical Trials
1,149 Total Patients Enrolled
2 Trials studying Smoldering Multiple Myeloma
83 Patients Enrolled for Smoldering Multiple Myeloma
The Leukemia and Lymphoma SocietyOTHER
72 Previous Clinical Trials
16,138 Total Patients Enrolled
2 Trials studying Smoldering Multiple Myeloma
1,042 Patients Enrolled for Smoldering Multiple Myeloma
CelgeneIndustry Sponsor
625 Previous Clinical Trials
173,075 Total Patients Enrolled
4 Trials studying Smoldering Multiple Myeloma
242 Patients Enrolled for Smoldering Multiple Myeloma
Irene Ghobrial, MDPrincipal InvestigatorDana-Farber Cancer Institute
10 Previous Clinical Trials
32,004 Total Patients Enrolled
3 Trials studying Smoldering Multiple Myeloma
1,698 Patients Enrolled for Smoldering Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The level of M protein increases progressively over time.\n
Plasma cells are abnormally high in number and are clonal.
You have a serum free light chain ratio of 8 or greater.
You have smoldering myeloma with high risk markers based on the Mayo OR the Spanish criteria as described below.
You have a serum M protein level of 3 g/dL or greater.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.